Trials / Unknown
UnknownNCT05966025
Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
Evaluation of the Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- October 6 University · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Objective of this study is to determine the clinical benefits of itopride in improvement of MAFLD
Detailed description
the study will evaluate the possible benefits of itopride when added to pateints with metabolic associated fatty liver disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Itopride | itopride will be taken by pateints one time per day by dose 100 mg |
| DRUG | conventional therapy | will taken by patient in control group |
Timeline
- Start date
- 2023-12-28
- Primary completion
- 2024-12-01
- Completion
- 2025-12-01
- First posted
- 2023-07-28
- Last updated
- 2023-10-31
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05966025. Inclusion in this directory is not an endorsement.